PRTAのPER（株価収益率）は？

PROTHENA CORPORATION PLC（PRTA）は現在PER 13.46倍で取引されています。

PRTAのROE（自己資本利益率）は？

PROTHENA CORPORATION PLCのROEは-48.36%です。

PRTAの配当利回りは？

PROTHENA CORPORATION PLCの配当利回りは0.00%です。

PRTAの品質スコア（Quality Score）は？

当社のAIはPRTAの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

PRTAは今が買い時ですか？

当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

PRTAはどのセクターに属しますか？

PROTHENA CORPORATION PLCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

PRTA (NASDAQ) 株価分析 | PROTHENA CORPORATION PLC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

PRTA AI Analysis Summary

Our AI summary for PRTA: PROTHENA CORPORATION PLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 13.46, ROE of -48.36%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PRTA

PROTHENA CORPORATION PLC

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 8.12

-0.29 (-3.45%) Day Change

Watchlist Portfolio Compare Chart

13.46

P/E

0.01

D/E

-48.4%

ROE

-43.2%

ROA

0.00%

Div Yield

0.43

PEG

PROTHENA CORPORATION PLC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 8.12 Price -0.29 (-3.45%) Day Change	NEWS SCORE: 98

PRTA, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Deepscope 分析

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	8.12
PBV / Sector	1.41 / 5.20 GOOD
Earning Per Share	-2.79

PE / Sector	13.46 / 19.97
PEG or PE/Growth / Sector	0.43 / 1.22 GOOD
Average 1M Daily Value	4.95 M GREAT
Average 1W Daily Value	5.43 M GREAT

Timing Factors

14%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-260.92 / 98.71
NPM Average (%) / Sector	-649.97 / -1,721.76
NPM Change Average (%) / Sector	631.52 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-43.21 / 27.02
ROA Average (%) / Sector	-35.36 / -368.17
ROA Change Average (%) / Sector	58.67 / 5,404.12 GREAT
ROE (%) / Sector	-48.36 / 3.47
ROE Average (%) / Sector	-41.10 / 6.51
ROE Change Average (%) / Sector	59.31 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 08:00:21
Symbol	PRTA
Name	PROTHENA CORPORATION PLC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	52.35 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	440.29 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60

Phone: 353 1 236 2500

Website: https://www.prothena.com

Employees: 67

Sector: Healthcare >> Biotechnology

Description: Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.